|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||1,120.00 - 1,235.50|
|52 Week Range||994.80 - 1,486.00|
|PE Ratio (TTM)||58.90|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Genmab plans to own a bigger share of drugs in its early-stage pipeline as Europe's biggest biotechnology company prepares to reduce its reliance on a blockbuster cancer drug, marketed by partner Johnson & Johnson. Genmab has morphed from a cash-burning operation into a profitable business especially due to the success of blood cancer drug Darzalex, on which it is paid a royalty of 12 to 20 percent on sales of the drug. "We have the ambition to keep at least 50 percent of the ownership of all the coming drugs on our own hands and maybe we can take it to the finish line," said chief executive officer Jan van de Winkel, speaking to reporters before the group's annual shareholder meeting on Tuesday.
LONDON/MILAN (Reuters) - Mergers and acquisitions dominated European share trading on Tuesday, while strength in oil stocks after a pipeline shutdown helped lift a key regional benchmark index to five-week highs. The pan-European STOXX 600 index climbed 0.7 percent to its highest level since Nov. 9, while euro zone blue chip stocks rose 0.4 percent, helped by a late drop in the euro. Gemalto surged 34.6 percent after French tech consultancy Atos tabled an all-cash bid valuing the Dutch cybersecurity company at 4.3 billion euros.
Genmab was Europe's second biggest biotech company, until its partner Johnson & Johnson bought Switzerland's Actelion for $30 billion (£22.30 billion) this year and propelled the Danish antibody specialist to the top spot. Now some investors wonder if the same fate might await Genmab, worth $12 billion, given the soaraway success of its blood cancer drug Darzalex. J&J sells the drug and pays Genmab a royalty of 12 to 20 percent.
By Helen Reid LONDON (Reuters) - European shares enjoyed a recovery on Thursday, snapping their longest losing streak since October 2016 as the cyclical sectors which had driven a market-wide sell-off ...
Gains by cyclical sectors helped push European stocks higher on Thursday while heavy losses in Dixons Carphone after a profit warning dominated trading. Dixons Carphone shares plummeted as much as 29 percent after the mobile phone retailer downgraded expectations for full-year profit, reflecting tougher conditions in the mobile market as customers hold on to handsets for longer. "With the December results some way off and Black Friday week (of retail discounts) looming, Dixons will be under pressure to provide additional detail on today's complex variables in coming weeks," said Stifel analysts.